Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$6.52 USD
+0.38 (6.19%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.03 (0.46%) 6:48 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 181 - 200 ( 222 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
May Be Growing Closer to Data Catalysts and the Unfolding of Platform Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
CDK7 and CDK9 Inhibitors: A New Class of Drugs to Watch From AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Awaiting Data While Pivoting From Monotherapy to a Combination Approach
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
4Q/FY17 Financials; Increasing Focus on SY-1365 Ahead of Key Updates in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Incyte Deal and 2018 Data Catalysts Support our Positive Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
SY-1425 Potentially Better Positioned as Combo Agent for Genomically Defined AML and MDS; Reit Neutral and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Reassessing SY1425 Following Disappointing Data Readout at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Biotechnology - ASH 2017 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Q3 Financials; Eyes on Initial SY-1425 AML/MDS Data at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.